Literature DB >> 33391278

Mycobacterium bovis Bacille-Calmette-Guérin Infection Aggravates Atherosclerosis.

Moises A Huaman1, Joseph E Qualls2, Shinsmon Jose1, Stephanie M Schmidt2, Anissa Moussa1, David G Kuhel3, Eddy Konaniah3, Ravi K Komaravolu3, Carl J Fichtenbaum1, George S Deepe1, David Y Hui3.   

Abstract

Tuberculosis has been associated with increased risk of atherosclerotic cardiovascular disease. To examine whether mycobacterial infection exacerbates atherosclerosis development in experimental conditions, we infected low-density lipoprotein receptor knockout (Ldlr -/-) mice with Mycobacterium bovis Bacille-Calmette-Guérin (BCG), an attenuated strain of the Mycobacterium tuberculosis complex. Twelve-week old male Ldlr -/- mice were infected with BCG (0.3-3.0x106 colony-forming units) via the intranasal route. Mice were subsequently fed a western-type diet containing 21% fat and 0.2% cholesterol for up to 16 weeks. Age-matched uninfected Ldlr -/- mice fed with an identical diet served as controls. Atherosclerotic lesions in aorta were examined using Oil Red O staining. Changes induced by BCG infection on the immunophenotyping profile of circulating T lymphocytes and monocytes were assessed using flow cytometry. BCG infection increased atherosclerotic lesions in en face aorta after 8 weeks (plaque ratio; 0.021±0.01 vs. 0.013±0.01; p = 0.011) and 16 weeks (plaque ratio, 0.15±0.13 vs. 0.06±0.02; p = 0.003). No significant differences in plasma cholesterol or triglyceride levels were observed between infected and uninfected mice. Compared to uninfected mice, BCG infection increased systemic CD4/CD8 T cell ratio and the proportion of Ly6Clow non-classical monocytes at weeks 8 and 16. Aortic plaque ratios correlated with CD4/CD8 T cell ratios (Spearman's rho = 0.498; p = 0.001) and the proportion of Ly6Clow non-classical monocytes (Spearman's rho = 0.629; p < 0.001) at week 16. In conclusion, BCG infection expanded the proportion of CD4+ T cell and Ly6Clow monocytes, and aggravated atherosclerosis formation in the aortas of hyperlipidemic Ldlr -/- mice. Our results indicate that mycobacterial infection is capable of enhancing atherosclerosis development.
Copyright © 2020 Huaman, Qualls, Jose, Schmidt, Moussa, Kuhel, Konaniah, Komaravolu, Fichtenbaum, Deepe and Hui.

Entities:  

Keywords:  Bacille-Calmette-Guérin; T cells; atherosclerosis; inflammation; monocytes; mycobacterium; tuberculosis

Year:  2020        PMID: 33391278      PMCID: PMC7775372          DOI: 10.3389/fimmu.2020.607957

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  50 in total

1.  Latent tuberculosis infection among patients with coronary artery stenosis: A case-Control study.

Authors:  Ahmad Farooq Alsayed Hasanain; Khalid M El-Maghraby; Ali A H Zayed; Amany M A Nafee; Sherif M Abdel-Aal; Sally M Bakkar
Journal:  Int J Mycobacteriol       Date:  2018 Apr-Jun

Review 2.  Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week.

Authors:  Peter Libby; Joseph Loscalzo; Paul M Ridker; Michael E Farkouh; Priscilla Y Hsue; Valentin Fuster; Ahmed A Hasan; Salomon Amar
Journal:  J Am Coll Cardiol       Date:  2018-10-23       Impact factor: 24.094

3.  Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.

Authors:  T C Moazed; L A Campbell; M E Rosenfeld; J T Grayston; C C Kuo
Journal:  J Infect Dis       Date:  1999-07       Impact factor: 5.226

4.  Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes.

Authors:  Siroon Bekkering; Jessica Quintin; Leo A B Joosten; Jos W M van der Meer; Mihai G Netea; Niels P Riksen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-06-05       Impact factor: 8.311

5.  Porphyromonas gingivalis accelerates inflammatory atherosclerosis in the innominate artery of ApoE deficient mice.

Authors:  Chie Hayashi; Jason Viereck; Ning Hua; Alkystis Phinikaridou; Andrés G Madrigal; Frank C Gibson; James A Hamilton; Caroline A Genco
Journal:  Atherosclerosis       Date:  2010-12-22       Impact factor: 5.162

6.  Tuberculosis increases the risk of peripheral arterial disease: A nationwide population-based study.

Authors:  Sheng-Huei Wang; Wu-Chien Chien; Chi-Hsiang Chung; Fu-Huang Lin; Chung-Kan Peng; Chih-Feng Chian; Chih-Hao Shen
Journal:  Respirology       Date:  2017-07-05       Impact factor: 6.424

7.  Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization.

Authors:  Hannah Priyadarshini Gideon; JiaYao Phuah; Amy J Myers; Bryan D Bryson; Mark A Rodgers; M Teresa Coleman; Pauline Maiello; Tara Rutledge; Simeone Marino; Sarah M Fortune; Denise E Kirschner; Philana Ling Lin; JoAnne L Flynn
Journal:  PLoS Pathog       Date:  2015-01-22       Impact factor: 6.823

Review 8.  The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.

Authors:  Rein M G J Houben; Peter J Dodd
Journal:  PLoS Med       Date:  2016-10-25       Impact factor: 11.069

9.  MT4-MMP deficiency increases patrolling monocyte recruitment to early lesions and accelerates atherosclerosis.

Authors:  Cristina Clemente; Cristina Rius; Laura Alonso-Herranz; Mara Martín-Alonso; Ángela Pollán; Emilio Camafeita; Fernando Martínez; Rubén A Mota; Vanessa Núñez; Cristina Rodríguez; Motoharu Seiki; José Martínez-González; Vicente Andrés; Mercedes Ricote; Alicia G Arroyo
Journal:  Nat Commun       Date:  2018-03-02       Impact factor: 14.919

Review 10.  Defining trained immunity and its role in health and disease.

Authors:  Mihai G Netea; Jorge Domínguez-Andrés; Luis B Barreiro; Triantafyllos Chavakis; Maziar Divangahi; Elaine Fuchs; Leo A B Joosten; Jos W M van der Meer; Musa M Mhlanga; Willem J M Mulder; Niels P Riksen; Andreas Schlitzer; Joachim L Schultze; Christine Stabell Benn; Joseph C Sun; Ramnik J Xavier; Eicke Latz
Journal:  Nat Rev Immunol       Date:  2020-03-04       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.